Light Horse Therapeutics Debuts With $62 Million Series A Financing
Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures and included Mubadala Capital as well as three strategic investors: Bristol-Myers Squibb Co, Taiho Ventures, and AbbVie. Light Horse is the latest company started by Versant’s Inception Discovery Engine.